The shares of Sempra Energy (NYSE:SRE) has been pegged with a rating of Buy by BofA/Merrill in its latest research note that was published on October 11th, 2018. BofA/Merrill wasn’t the only research firm that published a report of Sempra Energy, with other equities research analysts also giving their opinion on the stock. Wells Fargo advised investors in its research note published on August 20th, 2018, to Outperform the SRE stock. The stock had earned Equal-Weight rating from Morgan Stanley when it published its report on August 10th, 2018. The stock was given Market Perform rating by Wells Fargo in its report released on June 12th, 2018. Argus was of a view that SRE is Buy in its latest report on May 21st, 2018. BofA/Merrill thinks that SRE is worth Neutral rating. This was contained in the firm’s report on December 22nd, 2017.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 3 believe it has the potential for further growth, thus rating it as Hold while 6 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $132.90. The price of the stock the last time has raised by 30.55% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 65.17.
The shares of the company added by 0.56% during the trading session on Monday, reaching a low of $130.31 while ending the day at $131.18. During the trading session, a total of 1.68 million shares were traded which represents a -4% decline from the average session volume which is 1.62M shares. SRE had ended its last session trading at 130.45. Sempra Energy currently has a market cap of $36.07B, while its P/E ratio stands at 34.98, while its P/E earnings growth sits at 3.11, with a beta of 0.53. Sempra Energy debt-to-equity ratio currently stands at 1.62, while its quick ratio hovers at 0.40. SRE 52-week low price stands at $100.49 while its 52-week high price is $131.77.
The company in its last quarterly report recorded $1.92 earnings per share which is above the $1.68 predicted by most analysts. The Sempra Energy generated $2,898.00 million in revenue during the last quarter, which is slightly lower than the $3,144.13 million predicted by analysts. In the second quarter last year, the firm recorded $1.56 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 18.75%. Sempra Energy has the potential to record 3.75 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Citigroup published a research note on February 20th, 2019 where it informed investors and clients that Pfizer Inc. (NYSE:PFE) is now rated as Neutral. Their price target on the stock stands at $41. Wells Fargo also rated PFE as Upgrade on August 20th, 2018, with its price target of $40 suggesting that PFE could surge by 7.58% from its current share price. Even though the stock has been trading at $41.47/share, analysts expect it to surge higher by 0.29% to reach $45.00/share. It started the day trading at $41.71 and traded between $41.28 and $41.59 throughout the trading session.
A look at its technical shows that PFE’s 50-day SMA is 41.43 while its 200-day SMA stands at 42.50. The stock has a high of $46.47 for the year while the low is $35.32. The company’s P/E ratio currently sits at 23.03, while the P/B ratio is 3.99. At the moment, only of Pfizer Inc. shares were sold short. The company’s average trading volume currently stands at 23.36M shares, which means that the short-interest ratio is just 2.04 days. Over the past seven days, the company moved, with its shift of 2.51%. Looking further, the stock has dropped -2.37% over the past 90 days while it lost -3.08% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc sold more PFE shares, decreasing its portfolio by -0.34% during the last quarter. This move now sees The Vanguard Group Inc selling -1,488,549 shares in the last quarter, thus it now holds 442,134,056 shares of PFE, with a total valuation of $17,955,064,014. SSgA Funds Management Inc meanwhile bought more PFE shares in the recently filed quarter, changing its stake to $12,080,090,483 worth of shares. BlackRock Fund Advisors followed the path by decreasing its PFE portfolio by -2.31% in the quarter. This means that BlackRock Fund Advisors sold -6,607,970 shares in the last quarter and now controls 279,203,139 shares of the PFE stock, with the valuation hitting $11,338,439,475.
Similarly, T Rowe Price Associates Inc decreased its Pfizer Inc. shares by -2.84% during the recently filed quarter. After selling -3,127,601 shares in the last quarter, the firm now controls 107,080,908 shares of Pfizer Inc. which are valued at $4,348,555,674. In the same vein, Geode Capital Management LLC increased its Pfizer Inc. shares by during the most recent reported quarter. The firm bought 8,801,937 shares during the quarter which increased its stakes to 84,010,848 shares and is now valued at $3,411,680,537. Following these latest developments, around 0.10% of Pfizer Inc. stocks are owned by institutional investors and hedge funds.